![]() Results: Idarucizumab patients were older than andexanet alfa patients (median age 81 vs 77 years p < 0.001), and less likely to experience intracranial hemorrhage (ICH) (37.1%vs 73.8% p = 0.001). Inverse of treatment probability weighting (IPTW) method was used to balance patient and clinical characteristics between treatment cohorts. ![]() Methods: This retrospective study utilizing Premier Healthcare Database (PHD) included patients aged ≥18 years on direct oral anticoagulants (DOACs) who experienced life-threatening bleeds, discharged from the hospital during -, and received idarucizumab or andexanet alfa. Purpose: To assess costs and healthcare resource utilization (HCRU) associated with the use of idarucizumab for the reversal of dabigatran and andexanet alfa for the reversal of direct oral Factor Xa inhibitors.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |